-transparent.png){kind=logo}
The effect of Y-516 on the hyperactivity induced by dopamine injected bilaterally into the nucleus accumbens was compared with those of clocapramine (CCP), haloperidol (HPD) and chlorpromazine (CPZ). Dopamine (5-50 micrograms) injected into the nucleus accumbens induced a dose-dependent hyperactivity following pretreatment with nialamide (100 mg/kg, i.p., 2 hr). The hyperactivity induced by 10 micrograms of dopamine was antagonized by the i.p. administration of Y-516 (0.5-1.0 mg/kg), CCP (5-25 mg/kg), HPD (0.05-0.5 mg/kg) and CPZ (1-5 mg/kg) in a dose-dependent manner. The ED50 values of Y-516, CCP, HPD and CPZ were 0.85, 16.5, 0.098 and 2.53 mg/kg, respectively. These results suggest that Y-516 has a potential inhibitory effect on the mesolimbic dopaminergic system and may be a beneficial neuroleptic drugs.
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
September 1976,
European journal of pharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
November 1978,
British journal of pharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
April 1986,
The Journal of pharmacology and experimental therapeutics,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
December 1982,
Naunyn-Schmiedeberg's archives of pharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
February 1995,
Neuroscience,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
September 1994,
European journal of pharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
January 1979,
Neuropharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
August 1988,
Behavioral neuroscience,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
January 1984,
Psychopharmacology,
T Morimoto, and
Y Morimoto, and
T Fukuda, and
M Setoguchi
May 2009,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
